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INTRODUCTION
In the presence of hepatic disease, the metabolic
homeostasis of glucose is impaired as a result of
metabolic disorders such as diabetes mellitus (1-4).
A number of recent publications have reported an
increased frequency of glucose intolerance with hy-
perinsulinemia in liver cirrhosis (5, 6). The inci-
dence of a diabetic response to a standard oral glu-
cose tolerance test was 4.4% after a 2-year and 21.2%
after a 4-year follow-up in stable cirrhosis (5). The
patient with cirrhosis and diabetes mellitus suffers
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from more frequent complications, which can cause
death (7-9). The high prevalence of diabetes is due
to the insulin resistance of liver cirrhosis (10). In
general, insulin resistance is considered to be com-
posed of the following three metabolic defects ; 1)
reduced glucose uptake by the peripheral (muscle)
tissues ; 2) decreased splanchnic (hepatic) glucose
uptake ; 3) overproduction of glucose by the liver
(11). Imano, et al. showed that splanchnic (hepatic)
glucose uptake in patients with liver cirrhosis was
markedly decreased compared with normal, and pe-
ripheral (muscle) glucose uptake was also decreased
in liver cirrhosis (12). The mechanisms by which
liver cirrhosis produces insulin resistance and dia-
betes mellitus have not been clearly established. In
case of animal model, liver cirrhosis was induced in
male Sprague-Dawley rats by intraperitoneal injec-
tion of CCl4 (13). Then, the aim of this work was to
examine the relationship to insulin resistance be-
tween liver and muscle in CCl4-induced liver cir-
rhosis.
MATERIALS AND METHODS
Animals
All rats were cared for in accordance with the
NIH Guidelines for care and use of Laboratory ani-
mals. The protocol was approved by the University
of Tokushima animal Care and Use Committee.
Thirty six male Sprague-Dawley (SD) rats, 5 weeks
of age (weight 130-150 g) were purchased from Ja-
pan SLC (Hamamatsu, Japan) and were housed in
individual cages kept at 231under 12-hour
dark/light cycles, with free access to standard labo-
ratory chow and tap water. The animals were di-
vided into 2 groups. Eighteen rats received intrap-
eritoneal injection of 2 ml of soybean oil containing
of 0.5 ml of CCl4 twice a week for 20 weeks (CCl4
group). The remaining 18 rats received intraperito-
neal injections 2 ml of soybean oil twice a week for
20 weeks (control group). The amount of CCl4 was
adjusted according to the change in body weight
(BW). The initial dose in 5 and 6 week old rats was
0.5 ml/kgBW, increasing to 1.0 ml/kgBW in 7 to 24
week-old rats. Moreover, glucose metabolism was
evaluated by using oral glucose tolerance test, he-
patic glucose uptake and early-insulin secretion un-
der a hyperinsulinemic euglycemic clamp with oral
glucose load, and insulin-stimulated glucose utiliza-
tion methods.
Standard oral glucose tolerance test (OGTT) and
capability of glucose storage in liver
Control (n=6) and CCl4-induced (n=6) rats at 24
weeks old were subjected to an oral glucose load of
2 g/kgBW. Catheterization was performed as de-
scribed previously (14). In the glucose loading
study, under sodium pentobarbital anesthesia (50
mg/kgBW), a silicon rubber catheter was inserted
into the left femoral vein, and the line of the catheter
was led out through subcutaneous tissue to an intra-
venous hyperalimentation (IVH) kit (Bio-Cannula ;
Bio-Medica, Osaka, Japan). On the fifth day after
catheterization, tests were conducted after an over-
night fast and while the animals were conscious.
Blood sample for glucose and immunoreactive insu-
lin determination were collected from the femoral
vein in microtubes containing EDTA at 0, 15, 30,
60, 120, and 180 min. Moreover, on the fifth day
after the study, blood samples were collected under
nonanesthesia from the tail vein for the measure-
ment of plasma glucose, insulin and glucagon lev-
els, and under diethyl ether anesthesia from the left
jugular vein for the measurement of clinical parame-
ter. Rats were subsequently sacrificed for harvest
and weight measurement liver, visceral fat and pan-
creatic samples.
Within 2 wk of sampling, the liver tissues were
analyzed by microscopic examination after hematox-
ylin-eosin staining and AZAN staining to evaluate
the degree of hepatic fibrosis (with tissue necrosis,
regeneration nodules, extensive bridging fibrosis,
and no signs of acute inflammation). All samples
from kidney, esophagus, and small and large intes-
tines were normal.
Glycogen was measured as previously reported
(15). Samples (50 mg) of the liver were incubated
at 85in 0.5 ml of 0.5M-NaOH for 20 min. After
cooling, 0.15 ml was mixed with the same amount
of acetate buffer to make a final pH of 4.7. The sam-
ples were incubated at 37for 60 min with amylo-
glucosidase (0.2 mg/ml). The precipitated proteins
were eliminated by centrifugation at 8,000 g for 10
min. The glucose produced was measured by the
glucose oxidase method (16).
Plasma glucose levels were determined by the glu-
cose oxidase method (Advantage II, Roche Diagnos-
tics, Germany), and insulin and glucagon levels were
determined by a commercially available ELISA kit
(Morinaga, Yokohama, Japan) and (WAKO Osaka,
Japan), respectively. Serum alkaline phosphatase, as-
partate aminotransferase, alanine aminotransferase,
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total bilirubin, creatinine, blood urea nitrogen, total
protein, albumin, triacylglycerol, total cholesterol,
free fatty acid were measured using the several kit
(WAKO, Osaka, Japan).
Hyperinsulinemic euglycemic clamp study and meas-
urement of early insulin secretion
In the clamp study, silicon rubber catheters (FT-
025, Bio-Medica) were inserted into the left femoral
vein and into the left jugular vein at 24 weeks old
rat, and the clamp study was conducted on the 5th
day after catheterization. Catheterized rats were kept
in a special IVH cage (BG-781, Bio-Medica) and
were continuously infused with physiologic saline
until the test. Insulin-mediated whole-body glucose
uptake was measured in conscious rats using the hy-
perinsulinemic euglycemic clamp technique as re-
ported previously (17). After an overnight fast, blood
samples were drawn at baseline to determine fasting
plasma glucose and C-peptide levels. Blood samples
for determination of plasma glucose level were ob-
tained from the catheter in the femoral vein at 3-
minute intervals throughout the study. Data on total
body glucose uptake were represented by the mean
values of last 20 minutes for the glucose infusion
rate (GIR) at 120 min. After determination of base-
line GIR during the clamp, glucose was orally ad-
ministrated at a dose of 0.2 g/kgBW (18). Thereaf-
ter, the clamp was continued and the extent of de-
crease of GIR was monitored for 1.5 hours in order
to evaluate hepatic glucose uptake (HGU), which
was employed as an indicator of insulin sensitivity
in the liver. Total HGU was evaluated in this clamp
study, as previously described in detail (19). Fur-
thermore, to evaluate the ability of endogeneous
early-phase insulin secretion, serum C-peptide lev-
els were measured at 0 and 10 min during a clamp
with oral glucose load study (20). Serum C-peptide
levels were measured by a C-peptide radioimmu-
noassay (RIA) kit (Linco Research, St. Louis, MO).
Determination of insulin-stimulated glucose utiliza-
tion during clamp study
The glucose utilization index for peripheral tis-
sues (gastrocnemius muscle, diaphragm, epididy-
mal fat pads, musculus quadratus lumborum) was
measured in the same group of rats during another
hyperinsulinemic-euglycemic clamp test using the
2-deoxy-D-[1-3H] glucose ([3H]2DG) technique as
described by Ferre, et al. (21) and James, et al.
(22). At the end of the clamp test, peripheral tis-
sues and blood samples were rapidly treated, and
tissue glucose uptake (defined as the glucose meta-
bolic index, Rg’) was calculated, as previously de-
scribed in detail (17). Tissue glucose uptake was cal-
culated using the following equation described by
Rg’ (μmol/100 g/min)
=CpCm* (60)/(0-60) Cp*(t) dt
where Cp is the steady state plasma glucose con-
centration over a 60 min period of observation
(mmol/L) ; Cm* is tissue accumulation of [3H]2DG
6-phosphate per unit mass at 60 min (dpm/mg wet
weight) ; Cp*(t) is the plasma [3H]2DG concentra-
tion (dpm/mL) ; and t equals 0 when the tracer is
administered as a bolus.
Statistical analysis
All results were expressed as meanSEM. The
statistical significance of the differences in mean
values between the control and CCl4 groups were
evaluated using Student t -test by StatView software
(windows, version 5.0).
RESULTS
1, Body and organ weight and clinical chemistry
Body weight in CCl4 group was significantly lower
than that in control group although the liver and
pancreas weights significantly increased in CCl4
group (Table 1). The irregularity of hepatic surface,
the obtuse angle edge and the atrophy of the vol-
ume were recognized. Hepatic lobule structures in
CCl4 group were damaged with obvious collagen fi-
brils and pseudolobule formation, which were char-
acteristic of liver cirrhosis (Fig. 1). Total bilirubin
(T-Bil), aspartate aminotransferase (AST), alanine
Table 1 Body and organ weight, and hepatic glycogen content
in 24 weeks old CCl4 and control rat
Control CCl4
BW (g) 57610 4862 **
Liver (g/kgBW) 22.80.2 29.31.3 *
Pancreas (g/kgBW) 2.00.2 2.50.5 **
Soleus muscle (g/kgBW) 0.90.1 0.90.1
Mesenteric fat (g/kgBW) 16.32.1 16.01.3
Epididymal fat (g/kgBW) 17.62.1 13.21.7
Retroperitoneal fat (g/kgBW) 24.42.0 16.72.9
Glycogen contents in liver
(nmol/g tissue) 345.1
121.4 34.66.1 *
Results are meanSE. n=6 per group. *p0.05, ** p0.001
versus control.
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aminotransferase (ALT), alkaline phosphatase (ALP),
total cholesterol (T-cho) and glucagons were signifi-
cantly increased, and triglyceride (TG) was signifi-
cantly decreased in CCl4 group (Table 2). Further-
more, the amount of liver glycogen in the CCl4
group was lower than that in control (p0.05)
(Table 2).
2, Standard oral glucose tolerance test (OGTT)
There was no significant difference between two
groups (CCl4 and control) in regard to plasma glu-
cose levels during the OGTT (Fig. 2A). Plasma in-
sulin levels at 15 min during the OGTT were signifi-
cantly increased in CCl4 group (5.600.62 ng/ml)
compared with those obtained in control groups
(2.870.73 ng/ml, p0.01) (Fig. 2B, 2C). Area un-
der the curve of plasma insulin levels for 180 min
was significantly higher in CCl4 group than control
group during OGTT.
Table 2 Plasma Parameters in 24 weeks old CCl4 and control rat
Control CCl4
T-Bil (mg/dl) 0.030.004 0.260.07 *
AST (IU/L) 11113 882117 **
ALT (IU/L) 693 50260 **
ALP (IU/L) 58778 1410108 **
TP (g/dl) 6.70.1 6.60.1
Alb (g/dl) 3.80.03 3.80.02
BUN (mg/dl) 22.20.8 9.11.2
Cre (mg/dl) 0.340.01 0.330.02
T-cho (mg/dl) 755 1257 **
TG (mg/dl) 19218 474 **
Insulin (ng/ml) 1.800.33 2.070.25
Glucagon (pg/dl) 60.78.1 112.96.7 *
FFA (mEq/l) 0.760.18 0.970.09
ALP, alkaline phosphatase ; AST, aspartate aminotransferase ;
ALT, alanine aminotransferase ; T-Bil, total bilirubin ; Cre, cre-
atinine ; BUN, blood urea nitrogen ; TP, total protein ; Alb, albu-
min ; TG, triacylglycerol ; T-Cho ; total cholesterol ; FFA, free
fatty acid.
Results are meanSE, n=6 per group. *p0.05, ** p0.001
versus control.
A
B
C
Fig. 2 Changes in plasma glucose and insulin levels during oral
glucose tolerance test in 24 weeks old CCl4 - induced rat
(A) Plasma glucose and (B) plasma insulin levels in CCl4 - induced
rat and control rat. (C) Incremental ratio of insulin (IRI) was
calculated using the formula : IRI (15 minutes)-IRI (0 minute).
Results are meanSE, n=6 per group. *p0.05, **p0.01
versus control.
A B
Fig. 1 Histopathological evaluation of the livers in 24 weeks old CCl4 - induced rat
Azan staining was performed for histopathological characteristics of liver in control rat (A) and CCl4 injection rat (B). Note the pres-
ence of hepatic fibrosis (arrow) in (B). Scale size is 100 μm. Original magnification100.
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3, Glucose utilization and early-phase insulin secre-
tion during clamp study
Insulin sensitivity was evaluated by hyperinsuline-
mic euglycemic clamp test with oral glucose load, as
described in Materials and Method. The glucose in-
fusion rate (GIR), which reflected the insulin sen-
sitivity in peripheral tissues, was identical in both
cirrhotic and control rats (Fig. 3A). In contrast, the
rate of hepatic glucose uptake (HGU), which might
reflect insulin sensitivity in the liver, was significantly
lower in CCl4 group than in control group (Fig. 3B).
Furthermore, changes in C-peptide levels, to evalu-
ate early-phase insulin secretion, during the clamp
with oral glucose load are shown in Fig. 3C-3E. The
increase in C-peptide response (CPR) at 10 minutes
was enhanced in CCl4 groups than those in control
groups.
4, Glucose metabolic index
The glucose metabolic index (Rg) was considered
as representative of insulin-stimulated glucose up-
take in different types of tissue. The Rg in gastroc-
nemius muscle and epididymal fat pads (Fig. 4),
A B C
D E
Fig. 3 Measurement of insulin resistance and early -phase insulin secretion during hyperinsulinemic-euglycemic clamp in 24 weeks
old CCl4 - induced rat.
(A) Glucose infusion rate (GIR). (B) Hepatic glucose uptake (HGU). (C) Incremental ratio of C-peptide response (CPR) was calculated
using the formula : CPR (10 minutes)-CPR (0 minute). Changes in serum CPR levels during clamp at baseline (before clamp), steady
state (0 minute), and 10 minutes in control rat (D) and rat with CCl4 injection (E). Results are meanSE, n=6 per group. * p0.01
versus control.
A B
Fig. 4 Insulin-stimulated glucose utilization during clamp
2-deoxyglucose (2-DG) uptake in skeletal muscle (A) and white adipose tissue (B). Results are meanSE, n=6 per group.
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diaphragm and musculus quadratus lumborum (data
not shown) did not show any differences in both
groups.
DISCUSSION
Insulin resistance in target organ such as muscle
or adipose tissue and hyperinsulinemia seem to be
the pathophysiologic bases of diabetes in liver dis-
ease. Moreover, an impaired response of the islet
beta cells of the pancreas and hepatic insulin resis-
tance are also contributory factors. In this study, cir-
rhosis was induced in rats by intraperitoneal injec-
tion of CCl4 for 19 weeks. The model of cirrhosis
induced experimentally by chronic intoxication with
CCl4 has been widely used for studies of morphol-
ogy, pathophysiology and pharmacology of liver dis-
ease. Laboratory data and pathological findings were
similar to the previous reports (23, 24).
We simultaneously measured hepatic glucose up-
take (HGU) by using the euglycemic hyperinsuline-
mic clamp with oral glucose load. HGU in cirrhosis
was much lower than that in control. Therefore, the
amounts of hepatic glycogen in liver cirrhosis were
lower than those in normal. There were no differ-
ences in both glucose infusion rate (GIR) and glu-
cose uptake of peripheral tissue (muscle and adi-
pose tissue) between cirrhosis and control groups.
Accordingly there was not insulin resistance in skele-
tal muscle in this experimental study. Holland-
Fischer, et al. reported the muscle insulin-dependent
glucose transporter GLUT4 protein content in the
cirrhosis group was not different from that the con-
trols (25), which might explain our results. How-
ever, Imano, et al. showed that splanchnic (hepatic)
glucose uptake in patients with liver cirrhosis was
markedly decreased compared with normal, and pe-
ripheral (muscle) glucose uptake was also decreased
in liver cirrhosis (12). The difference of two reports
concerning muscle glucose uptake might be depend-
ent on the duration of liver cirrhosis. The duration
of liver cirrhosis in human was longer than that in
these experimental rats. Then hepatic insulin resis-
tance might be recognized in the early stage of liver
cirrhosis and successively peripheral (muscle) in-
sulin resistance might be appended in the late stage
of liver cirrhosis.
The plasma C-peptide level of the early-phase in-
sulin secretion at 10 minutes after glucose load dur-
ing clamp was significantly higher in CCl4 than in
control. Similarly, plasma insulin levels increased at
15 min during OGTT in CCl4 group, and subse-
quently maintained high concentrations compared
with control group. It is reported that importance
role of rapid insulin secretion suppressed hepatic
glucose production (26, 27). Consequently, this re-
sponse induces the suppression of postprandial hy-
perglycemia. In the present study, it was not ob-
served in OGTT and peripheral insulin-induced glu-
cose uptake was normal. These results raise the pos-
sibility that increased insulin levels might compen-
sate for hepatic insulin resistance.
Hyperinsulinemia in cirrhosis may be caused by
two factors. One is decrease of hepatic clearance of
insulin. A large number of investigators have, direc-
tory or indirectory, showed that reduced insulin
clearance by the liver cirrhosis, contributes to hy-
perinsulinemia (28-31). It has been proposed that
insulin extraction by damaged liver and portosys-
temic shunts result in hyperinsulinemia which is
potentiated by raised levels of contra-insulin hor-
mones (glucagon, insulin-like growth factor, free
fatty acids and cytokines)(3, 7, 32, 33). The other
is increase of insulin secretion from islet. A recently
study reports that in patients with Child B grade
liver cirrhosis the hyperinsulinemia may be pro-
duced by an increase of the pancreatic beta-cell sen-
sitivity to glucose, whereas disturbance of hepatic
insulin extraction does not seem to have a signifi-
cant role (34). Moreover, serum human hepatocyte
growth factor (HGF) levels in patients with acute
hepatitis, chronic hepatitis and cirrhosis were found
to be slightly higher than those in normal subjects
(35). Garcia-Ocaña A., et al. showed that HGF over-
expression in the beta-cell specifically upregulates
insulin secretion in response to glucose, independ-
ent of islet size (36), although there were no signifi-
cant differences in the fasting insulin levels between
HGF transgenic mice and control. Similar results
were obtained in the present study (37). Therefore,
CCl4-induced rat may be chronic compensatory
hyperinsulinemia until the islet beta cells are ex-
hausted. However we could not examine the islet
size and serum HGF levels. Further examination
was needed in these points.
In conclusion, hepatic glucose uptake was much
lower in CCl4-induced rat than that in control al-
though peripheral (muscle) glucose uptake was not
decreased in this study. These data suggested that
increased early insulin secretion might compensate
adequately for hepatic insulin resistance. In a chroni-
cally condition, this compensation may be associ-
ated with reduced insulin content and developed
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systemic insulin resistance in liver cirrhosis. There-
fore, a long term observation is required to examine
the presence of muscle insulin resistance in liver
cirrhosis.
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